You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
眾生藥業(002317.SZ):用於治療甲型流感的ZSP1273片Ⅲ期臨牀研究已完成全部病例數入組
格隆匯 05-11 07:57

格隆匯5月11日丨有投資者在投資者互動平台向眾生藥業(002317.SZ)提問,“公司流感創新藥ZSP1273三期臨牀數據分析是否已完成?是否達到預期效果?樂睿靈產能多少、是否能滿足市場需求?”

眾生藥業回覆稱,用於治療甲型流感的ZSP1273片Ⅲ期臨牀研究已完成全部病例數入組,公司將繼續與各合作方加強溝通和協調,高效、科學推進項目進程,抓緊時間做好數據管理和統計分析工作。公司密切關注疾病動態情況,及時做好藥品生產和配送工作。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account